Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 11, 2002, Pages 581-588

  Yoshimura, Chie ^a   Nomura, Shosaku ^a   Kanazawa, Shigenori ^a   Kuwana, Midori ^a   Muramatsu, Mikiko ^a   Yamaguchi, Kazuyuki ^a   Fukuhara, Shirou ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cancer reactive CTLs; Fas FasL; HLA A2; Immunotherapy; Non small cell lung cancer

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN;

ADULT; AGED; ALLELE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL ISOLATION; CELL LABELING; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; JAPAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROLOGY; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036449301     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0381-y     Document Type: Article

References (56)

1. Arnett KL, Parham P (1995) HLA class I nucleotide sequence. Tissue Antigens 46:217-257
2. Beresford PJ, Xia Z, Greenberg AH, Lieberman J (1999) Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation. Immunity 10:585-594
3. Bixby DL, Yannelli JR (1998) CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer. Int J Cancer 78:685-694
4. + T cells by a self-derived peptide. Nature 378:295-298
5. Cheng J, Zhou T, Liu C (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762
6. Coulie PG, Brichard V, van Pel A, Wolfel T, Schneider J, Traversavi C, Mattei S, De Plaen E, Lurguin C, Szikora JP (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T-lymphocytes on HLA-A2 melanomas. J Exp Med 180:35-42
7. Dong R, Kimura A, Okubo R, Shinagawa H, Tamai H, Nishimura Y, Sasazuki T (1992) HLA-A and DPB1 loci confer susceptibility to Graves' disease. Hum Immunol 35:165-172
8. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA (1994) In vitro generation of human CTL specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:1071-1076
9. Eifuku R, Takenoyama M, Yoshino I, Imabayashi S, So T, Yasuda M, Sugaya M, Yasumoto K (2001) Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes. Int J Clin Oncol 6:34-39
10. Frasci G, Panza P, Comella P, Nicolella GP, Natale M, Pacilo C, Gravina A, Caputi V, Botti G, Comella G (1997) Cisplatin, gemcitabine, and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: A phase I study. Ann Oncol 8:1045-1048
11. Gunjatic S, Cai Z, Viguier M, Cheuaib S, Guillet JG, Choppin J (1998) Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 160:328-333
12. Hanagiri T, Yoshino I, Takenoyama M, So T, Fujie H, Imabayashi S, Eifuku R, Yoshimatsu T, Osaki T, Nakanishi R, Ichiyoshi Y, Nagashima A, Nomoto K, Yasumoto K (1998) Effects of interleukin-12 on the induction of cytotoxic T lymphocytes from the regional lymph node lymphocytes of patients with lung adenocarcinoma. Jpn J Cancer Res 89:192-198
13. Henderson BE, Ross RK, Pike MC (1991) Toward the primary prevention of cancer. Science 254:1131-1137
14. Ito M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A, Saito N, Itoh K (2000) Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 88:633-639
15. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233-243
16. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Muller KM (1997) Tumor regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 123:469-477
17. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P (1994) Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530
18. Karanikas V, Colau D, Baurain JF, Chiari R, Thonnard J, Gutierrez-Roelens I, Goffinet C, Van Schaftingen EV, Weynants P, Boon T, Coulie PG (2001) High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 61:3718-3724
19. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema G J, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T-cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515-3519
20. Kawasaki M, Kuwano K, Nakanishi Y, Hagimoto N, Takayama K, Pei XH, aeyama T, Yoshimi M, Hara N (2000) Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. Eur J Cancer 36:656-663
21. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H (1995) Metalloproteinase-mediated release of human Fas ligand. J Exp Med 182:1777-1783
22. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effector of type I IFNs. J Exp Med 189:1451-1460
23. Kerr JFR, Wyllie AH, Currie AR. (1972) Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
24. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH (1995a) Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 85:1562-1569
25. Knipping E, Krammer PH, Onel KB, Lehman TJ, Hysler E, Elkon KB (1995b) Level of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38:1735-1737
26. Komaki R, Scott C, Lee JS, Urtasun RC, Byhardt RW, Emami B, Andrac EJ, Asbell SO, Rotman M, Cox JD (1997) Impact of adding concurrent chemotherapy to hyperfractionated radio-therapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol 20:435-440
27. Koomagi R, Volm M (1999) Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84:239-243
28. Lebeau B, Chastang CL, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lamarie E (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74:38-45
29. Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Han JY, ParkGS, Deng M, Pi JH, Kim CS, Kim SH, Lee JY, Too NJ (1999) Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 24:3754-3760
30. Lowin B, Hahne M, Mattman C, Tshopp J (1994) Cytolytic T-cell toxicity is mediated through perforin and Fas lytic pathways. Nature 370:650-652
31. Maurer LH, Herndon II JE, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR (1997) Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small cell lung cancer: A Cancer and Leukemia Group B study. J Clin Oncol 15:3378-3387
32. Midis GP, Shen Y, Owen-Schaub LB (1996) Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 56:3870-3874
33. Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449-1456
34. Niehans GA, Brunner T, Frizelle SD, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA (1997) Human lung carcinomas express Fas ligand. Cancer Res 57:1007-1012
35. Nomura S, Matsuzaki T, Ozaki Y, Yamaoka M, Yoshimura C, Katsura K, Xie GL, Kgawa H, Ishida T, Fukuhara S (1998) Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood 91:3616-3622
36. O'Rourke MA (1997) Historical review of trials with vinorelbine in non-small-cell lung cancer. Oncology 11:20-27
37. Page A, Nakhle G, Mercier C, Verdant A, Page P, Dontigny L, Allard S, Gauthier JJ, Cossette R (1987) Surgical treatment of bronchiogenic carcinoma: The importance of staging in evaluating late survival. Can J Surg 30:96-99
38. 2+-independent T cell-mediated cytotoxicity. J Exp Med 177:195-200
39. Seki N, Hoshiro T, Kikuchi M, Hayashi A, Itoh K (1997) HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Cellular Immunol 175:101-110
40. Shresta S, Graubert TA, Thomas DA, Raptis SZ, Ley TJ (1999) Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity 10:595-605
41. Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76:959-962
42. So T, Takenoyama M, Sugaya M, Yasuda M, Eifuku R, Yoshimatsu T, Osaki T, Yasumoto K (2001) Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 32:39-46
43. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, Ganz T, Thoma-Vszynski S, Melian A, Bogdan C, Porcelli SA, Bloom BR, Krensky AM, Modlin RL (1998) An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282:121-125
44. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178
45. Tanaka M, Suda T, Takahashi T, Nagata S (1995) Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 14:1129-1135
46. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kumura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S (1996) Fas ligand in human serum. Nat Med 2:317-322
47. Terasaki PI, McClelland JD (1964) Microdroplet assay of human serum cytotoxins. Nature 204:998-1002
48. Tokunaga K, Ishikawa Y, Ogawa A, Wang H, Mitsunaga S, Moriyama S, Lin L, Bannai M, Watanabe Y, Kashiwase K, Tanaka H, Akaza T, Tadokoro K, Tsuji T (1997) Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 46:199-205
49. Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG (2001) Cancer Res 61:4761-4765
50. Trojan A, Tun-Kyi A, Odermatt B, Nestle FO, Stahel RA (2002) Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors. Lung Cancer 36:151-158
51. Valmori D, Lienard D, Waanders G, Rimold D, Cerottini JC, Romero P (1997) Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res 57:735-741
52. Van der Bruggen P, Traversari C, Chomez P, Lurguin C, De Plaen E, van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 254:1643-1647
53. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, DeSmet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
54. Yamazaki K, Spruill G, Rhoderick J, Spielman J, Savaraj N, Podack ER (1999) Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Cancer Res 59:4642-4650
55. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Guzdar AF, Eberlein TJ (1994) HER2/neuderived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 54:3387-3390
56. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, Edwards R, Headley E, Kim SH, O'Donnell JR, O'Dell R, Tornyos K, Kwaan HC (1981) Effect of sodium warfarin on survival in small cell carcinoma of the lung. JAMA 245:831-835